JP2010500406A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500406A5
JP2010500406A5 JP2009524638A JP2009524638A JP2010500406A5 JP 2010500406 A5 JP2010500406 A5 JP 2010500406A5 JP 2009524638 A JP2009524638 A JP 2009524638A JP 2009524638 A JP2009524638 A JP 2009524638A JP 2010500406 A5 JP2010500406 A5 JP 2010500406A5
Authority
JP
Japan
Prior art keywords
crystalline
formula
salt
compound
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009524638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500406A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017848 external-priority patent/WO2008021271A1/en
Publication of JP2010500406A publication Critical patent/JP2010500406A/ja
Publication of JP2010500406A5 publication Critical patent/JP2010500406A5/ja
Withdrawn legal-status Critical Current

Links

JP2009524638A 2006-08-14 2007-08-10 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩 Withdrawn JP2010500406A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14
PCT/US2007/017848 WO2008021271A1 (en) 2006-08-14 2007-08-10 Salts of 5 - ( l ( s ) -amino - 2 - hydroxyethyl ) -n- [ ( 2, 4 -difluorophenyl) -methyl] - 2 - [ 8 -methoxy - 2 - (trifluoromethyl) - 5 - quinoline] - 4 - oxazolecarboxamide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012137788A Division JP2012176989A (ja) 2006-08-14 2012-06-19 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩
JP2012247215A Division JP2013032394A (ja) 2006-08-14 2012-11-09 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩

Publications (2)

Publication Number Publication Date
JP2010500406A JP2010500406A (ja) 2010-01-07
JP2010500406A5 true JP2010500406A5 (cg-RX-API-DMAC7.html) 2012-08-09

Family

ID=38895795

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009524638A Withdrawn JP2010500406A (ja) 2006-08-14 2007-08-10 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩
JP2012137788A Withdrawn JP2012176989A (ja) 2006-08-14 2012-06-19 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩
JP2012247215A Pending JP2013032394A (ja) 2006-08-14 2012-11-09 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012137788A Withdrawn JP2012176989A (ja) 2006-08-14 2012-06-19 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩
JP2012247215A Pending JP2013032394A (ja) 2006-08-14 2012-11-09 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩

Country Status (11)

Country Link
US (1) US7956189B2 (cg-RX-API-DMAC7.html)
EP (1) EP2069337A1 (cg-RX-API-DMAC7.html)
JP (3) JP2010500406A (cg-RX-API-DMAC7.html)
CN (1) CN101522671A (cg-RX-API-DMAC7.html)
AR (1) AR062373A1 (cg-RX-API-DMAC7.html)
CA (1) CA2660703A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002366A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009001770A (cg-RX-API-DMAC7.html)
PE (1) PE20080424A1 (cg-RX-API-DMAC7.html)
TW (1) TW200819446A (cg-RX-API-DMAC7.html)
WO (1) WO2008021271A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609659C (en) 2005-05-26 2014-01-28 Neuron Systems, Inc. Azanaphthalenes, compositions and methods for treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2417993C9 (ru) * 2004-05-18 2011-10-10 Шеринг Корпорейшн Замещенные 2-хинолилоксазолы, пригодные в качестве ингибиторов фдэ4

Similar Documents

Publication Publication Date Title
JP2010500406A5 (cg-RX-API-DMAC7.html)
JP5889275B2 (ja) ラルテグラビル塩およびその結晶形
JP2005503386A5 (cg-RX-API-DMAC7.html)
JP2011512396A (ja) 新規な多形およびその調製方法
JP2012176989A (ja) 5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩
JP6779972B2 (ja) 呼吸器合胞体ウイルス(rsv)感染症の処置のためのn−[(3−アミノ−3−オキセタニル)メチル]−2−(2,3−ジヒドロ−1,1−ジオキシド−1,4−ベンゾチアゼピン−4(5h)−イル)−6−メチル−4−キナゾリンアミンの結晶形
JP2012176989A5 (cg-RX-API-DMAC7.html)
CN115461351A (zh) 金属-有机骨架的高产量合成
JP2024001115A (ja) オキサゾール化合物結晶
KR20170023417A (ko) L-카르노신 아연 착물의 제조 방법
WO2010069280A2 (en) A method for the preparation of tizanidine hydrochloride
JP2015512381A5 (cg-RX-API-DMAC7.html)
TWI331612B (en) Method for preparation of spherical support for olefin polymerization catalyst
WO2017092703A1 (zh) 制备无定型奥贝胆酸的方法
CN102093307A (zh) 法莫替丁共晶
US20090012296A1 (en) Processes for the preparation of crystalline form beta of imatinib mesylate
CN115461328A (zh) 用于制备激酶抑制剂的方法
JP4657393B2 (ja) ドキサゾシン・メシレートの新規な形態iii
JP7472024B2 (ja) ファソラセタムの固体形態
JP2010502682A5 (cg-RX-API-DMAC7.html)
CN109369691B (zh) 一种高温相变化合物及其制备方法和应用
JPH10101960A5 (cg-RX-API-DMAC7.html)
JP5827684B2 (ja) 2−[3−シアノ−4−(2−i−ブトキシ)フェニル]−4−メチル−5−チアゾール−カルボン酸(フェブキソスタット)の結晶形Aを調製するための方法
JP4115751B2 (ja) 微水ベンズイミダゾール系化合物の製法
CN109265355A (zh) 戊二胺辛二酸盐及其晶体